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The promyelocytic leukaemia gene PML is a pleiotropic tumour suppressor. We
have recently demonstrated that PML opposes mTOR-HIF1a-VEGF signalling in
hypoxia. To determine the relevance of PML-mTOR antagonism in tumourigen-
esis, we have intercrossed Pml null mice with Tsc2 heterozygous mice, which
develop kidney cysts and carcinomas exhibiting mTOR upregulation. We ﬁnd that
combined inactivation of Pml and Tsc2 results in aberrant TORC1 activity both in
pre-tumoural kidneys as well as in kidney lesions. Such increase correlates with a
marked acceleration in tumour progression, impacting on both the biology and
histology of kidney carcinomas. Also, Pml inactivation decreasesthe rate ofloss of
heterozygosity (LOH) for the wt Tsc2 allele. Interestingly, however, aberrant
TORC1 activity does not accelerate renal cystogenesis in Tsc2/Pml mutants.
Our data demonstrate that activation of mTOR is critical for tumour progression,
but not for tumour initiation in the kidney.
INTRODUCTION
Work from our laboratory has shown that PML opposes the Akt-
mTOR pathway at two levels: by promoting Akt depho-
sphorylation (Trotman et al, 2006) and by inhibiting mTOR
downstream Akt (Bernardi et al, 2006). In vivo, loss of Pml leads
to increased activity of nuclear Akt and accelerates prostate and
colon tumourigenesis in Pten
þ/  mice (Trotman et al, 2006).
However, whether PML exerted tumour suppressive functions
by directly antagonizing mTOR remained to be established.
The protein kinase mTOR exists in two complexes: mTORC1
is activated by growth factors and insulin through Akt to control
protein synthesis. Activation of mTORC1 is opposed by the
Tsc1/Tsc2 complex (Bhaskar and Hay, 2007) and in turn
attenuates Akt signalling through a negative feedback loop
(Huang and Manning, 2009). Conversely, mTORC2 phosphor-
ylates and activates Akt (Bhaskar and Hay, 2007), and the Tsc1/
Tsc2 complex is required for this activity (Huang and Manning,
2009).
On this basis, in order to understand if PML restrains
tumourigenesis by regulating mTORC1, we utilized a tumour
mouse model proposed to depend on aberrant activation of
mTOR, but not Akt. Tsc2
þ/  mice develop renal cysts and
carcinomas that display Tsc2 loss of heterozygosity (LOH) and
increased mTORC1 activity (Kobayashi et al, 1999; Onda et al,
1999), while Akt activity is suppressed (Harrington et al, 2005;
Manning et al, 2005). Notably, forced Akt activation by
decreased Pten dosage does not accelerate kidney tumourigen-
esis (Ma et al, 2005; Manning et al, 2005), although it enhances
the severity of liver haemangiomas that occur in some strains of
Tsc2
þ/  mice (Manning et al, 2005). These studies suggested
that some tumour types like kidney tumours may be exquisitely
sensitive to mTORC1 activation, while others, like prostate
tumours (Ma et al, 2005) or liver haemangioma (Manning et al,
2005), may beneﬁt from full activation of the pathway upstream
of mTOR.
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 /  mice with Tsc2
þ/  mice to assess if:
(i) loss of Pml impacted on kidney tumourigenesis by promoting
further mTORC1 activation; (ii) loss of Pml was sufﬁcient to tilt
the feedback balance and promote Akt activation in conjunction
with mTORC1 activation; (iii) compound Pml and Tsc2 loss
would accelerate tumour initiation and/or progression in the
kidney. We found that loss of Pml in Tsc2
þ/  mice enhances
mTORC1 but not Akt activation and accelerates the develop-
ment of aggressive kidney carcinomas while having little effect
on cysts formation. Thus, utilizing a direct genetic approach in
the mouse, we demonstrate that PML suppresses tumourigen-
esis through repression of mTOR, while mTORC1 hyper-
activation does not sufﬁce to initiate tumourigenesis in the
kidney.
RESULTS
Pml and Tsc2 cooperate in inhibiting mTORC1 in
kidney tubules
Compound inactivation of Pml and Tsc2 did not affect the
histology of adult mouse kidney (Supporting Information Fig
1A), but it affected mTORC1 activity. Phosphorylation of
ribosomalprotein S6waslowandconﬁnedtodiscretetubulesin
the kidney of wt and Tsc2
þ/  mice. In Pml
 /  mice, a small
increase in phospho-S6 was found, while a signiﬁcant increase
was observed in compound Pml
þ/ Tsc2
þ/  and Pml
 / Tsc2
þ/ 
mice (Fig 1A and B).
We have previously demonstrated that in conditions of
hypoxia, mTOR acquires partial nuclear localization and that
PML regulates the localization of mTOR (Bernardi et al, 2006).
Consistently, mTOR localized to both cytoplasm and nucleus in
kidney tubule cells under physiological oxygen concentrations,
and in the absence of Pml, the number of cells with nuclear
mTOR diminished (Fig 1C).
Like Tsc2 (Onda et al, 1999), Pml is expressed in speciﬁc
kidney tubules (Supporting Information Fig 1B and C) that
coexpress markers of distal tubules and collecting ducts
(Supporting Information Fig 1D, upper panels). Accordingly,
phospho-S6 staining in compound Pml
 / Tsc2
þ/  mice
colocalized with the same markers (Supporting Information
Fig 1D, lower panels), demonstrating that mTORC1 upregula-
tion in mutant mice occurs in the distal tubules and/or
collecting ducts.
Analysis of mTORC1 activity in other organs revealed that
total physiological levels of 4EBP1 and S6K are dramatically
higher in adult liver than in adult kidney (Supporting
Information Fig 2A). Consistently, it was recently observed
that mTORC1 activity in mouse kidney is high in the ﬁrst post-
natal days but decreases to minimal levels after P14 (Zhou et al,
2009). In spite of this, increased mTORC1 activity was
also observed in livers of compound Pml
 / Tsc2
þ/  mice
(Supporting Information Fig 2B and C), indicating the two genes
inhibit mTORC1 in the kidney but also in other organs.
In summary, inactivation of Pml and, more signiﬁcantly,
compound Pml and Tsc2 inactivation triggers mTORC1 activa-
tion in normal tissues.
Pml loss in kidney causes increased tumour progression
We next asked whether increased mTORC1 activity affects
tumour initiation. Tsc2
þ/  mice develop kidney cortical cysts
and adenocarcinomas with high mTORC1 activity starting at
approximately 6 months (Kobayashi et al, 1999; Onda et al,
1999). Surprisingly, despite increased mTORC1 activity in pre-
cystic Pml
 / Tsc2
þ/  kidneys, we did not detect a signiﬁcant
increase in the number of cysts and small carcinomas as
compared to Tsc2
þ/  mice at 6–8 months (Fig 2A). However, by
serial MRI, we observed that older Tsc2
þ/  animals developed
more tumour lesions in the absence of Pml (Fig 2B), while
Pml
þ/  and Pml
 /  littermates did not develop kidney tumours.
Tumour size, measured as the number of tumours exceeding
0.5cm in diameter, was also signiﬁcantly higher in compound
mutants (Fig 2C and D). These data suggest that a twofold
increase in mTORC1 activity does not affect cystogenesis but it
seemingly affects tumour progression.
Importantly, along with increased tumour size, tumours in
Pml
 / Tsc2
þ/  mice showed other features of aggressive
carcinomas. Kidney carcinomas from Tsc2
þ/  mice for example
display heterogeneous histological phenotypes within the same
tumour: a predominant phenotype of regular, cuboidal cells
arranged into a papillary architecture (Fig 2E, single arrow) is
often ﬂanked by a clear cell histotype (Fig 2E, double arrow). In
addition, some tumours show areas of elongated, ﬁbroblast-like
cells (Fig 2F), reminiscent of sarcomatoid change that in human
renal cell carcinoma correlates with tumour progression and
worse prognosis (de Peralta-Venturina et al, 2001). In
compound Pml
 / Tsc2
þ/  mice, we detected a small increase
in tumours with clear cell morphology (tumours with areas of
clear cell morphology: 66% in Tsc2
þ/  mice and 90% in
Pml
 / Tsc2
þ/  mice; p¼0.2), and a signiﬁcant increase in
tumours with sarcomatoid changes (Fig 2F), indicating that
tumours lacking Pml are more aggressive. Consistent with this
notion,tumoursfromcompoundPml
 / Tsc2
þ/ micedisplayed
increased microvessel density and proliferation rates (Fig 3A
and B), although they did not metastasize.
Despite the different phenotypes, tumours in Tsc2
þ/  and
Pml
 / Tsc2
þ/  mice likely originate from the same kidney
structures, as they express similarly gelsolin (Onda et al, 1999).
Speciﬁcally, a comparable number of cysts showed gelsolin
expression (Fig 3C) and in overt tumours, where gelsolin
expression varied among tumours areas (Wilson et al, 2005), no
signiﬁcant difference was observed in the absence of Pml
(Fig 3D, arrow). These data indicate that although cysts in
Tsc2
þ/  mice may originate from different structures, or
perhaps transdifferentiation processes occur within cysts and
tumours,theseprocessesarenotmodiﬁedintheabsenceofPml.
Taken together, our data indicate that increased mTORC1
activity in the kidney of compound Pml
 / Tsc2
þ/  mice does
not modify the incidence of cysts and small carcinomas but
accelerates tumour progression, as measured by several
parameters that correlate with aggressiveness in human kidney
tumours.
Finally, we also evaluated the frequency of liver haeman-
gioma. Tsc2
þ/  mice bred in our genetic background develop
very few liver haemangioma when older than 18 months.
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did not modify tumour incidence (data not shown).
Cysts and tumours lacking Pml display increased mTORC1
activity and decreased Tsc2 LOH
Next, we measured the phosphorylation status of proteins
that are regulated by mTORC1 and mTORC2 complexes. In
agreement with higher activation of mTORC1 in pre-cystic
kidneys of compound mutants mice (Fig 1A), a twofold increase
in mTORC1 activity was also observed in tumours from
Pml
 / Tsc2
þ/  mice (Fig 4A and B). Because loss of Pml
causes increased Akt activity (Trotman et al, 2006) while
activation of mTORC1 leads to its decrease (Harrington et al,
2005), we asked how loss of Pml would affect Akt status in
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Figure 1. Compound inactivation of Pml and Tsc2 causes increased activation of mTORC1 in the kidney cortex.
A. Immunohistochemical analysis of phospho-S6 on kidney from 8-month-old mice. 20  magnification is shown in the upper panels (scale bar: 100mM) and
higher magnification images of boxed areas in the lower panels (scale bar: 50mM).
B. Westernblotanalysisofwholekidneysfrom8-month-oldmice.Graphontheright: averageratiosofphospho/totalS6levelsinkidneyextracts from3to6mice
per genotype  SD. p-value, calculated by Student’s t-test, compares samples of the indicated genotype with the reference value of wt kidneys.
C. Immunohistochemical analysis of mTOR on kidney from 8-month-old mice (20  magnification, scale bar: 50mM). Arrows indicate cells with nuclear staining.
Graph on the right: percentage of cells/tubuli with cytoplasmic and nuclear staining, as opposed to only cytoplasmic staining. 10 fields/mouse were counted,
three mice/genotype. p-value was calculated by Student’s t-test.
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change in Akt phosphorylation in kidney or in kidney tumours,
either in the presence or absence of Pml or Tsc2 (Fig 4C and
Supporting Information Fig 3), indicating that renal Akt activity
remains low and not affected by the genetic inactivation of Pml
and/or Tsc2 as also documented in other Tsc mouse models
(Huang et al, 2009; Pollizzi et al, 2009).
mTORC1 activity was also increased in cysts lacking
Pml, because all cysts in Pml
 / Tsc2
þ/  mice displayed high-
phospho-S6 staining as compared to 60% in Tsc2
þ/  mice
Report
PML and mTOR in tumour progression
Tsc2+/-
Pml+/+ 
Tsc2+/-
Pml-/- 
Tsc2+/-
Pml+/- 
carcinomas
cysts
#
 
l
e
s
i
o
n
s
/
k
i
d
n
e
y
A
C
B
c
y
s
t
c
a
r
c
i
n
o
m
a
14-19 months
8-13 months
#
 
l
e
s
i
o
n
s
/
k
i
d
n
e
y
*
*
*P=0.02
Tsc2+/-
Pml+/+ 
Tsc2+/-
Pml-/- 
Tsc2+/-
Pml+/- 
#
 
b
i
g
 
l
e
s
i
o
n
s
/
k
i
d
n
e
y
14-19 months
*
*
*P=0.024
0.5
cm
0.5
cm
Tsc2+/- Pml+/+ 
Tsc2+/- Pml-/- 
D
Tsc2+/-
Pml+/+ 
Tsc2+/-
Pml-/- 
Tsc2+/-
Pml+/- 
E F
Tsc2+/-
Pml+/+ 
Tsc2+/-
Pml-/- 
Tsc2+/-
Pml+/- 
%
 
t
u
m
o
r
s
 
w
i
t
h
 
s
a
r
c
o
m
a
t
o
i
d
 
l
e
s
i
o
n
s
0
20
40
60
80
*
* *P=0.04
0
1
2
3
4
5
0
1
2
3
Tsc2+/-
Pml+/+ 
Tsc2+/-
Pml-/- 
Tsc2+/-
Pml+/- 
0
0,1
0,2
0,3
0,4
0,5
0,6
Figure 2. Inactivation of Pml in Tsc2
þ/  mice causes increased tumour progression.
A. Number of cysts and small carcinomas in 12 sections/kidney were measured in 10 mice/genotype (n¼20 kidneys) of 6–8 months  SD. On the right,
representative images of a cortical cyst and a cortical kidney carcinoma in a Tsc2
þ/  mouse (H&E staining; 20  magnification, scale bar: 200mM).
B. 12–14 mice/genotype/time range (n¼24–28 kidneys) were analysed by MRI. Fifteen frames were acquired for each mouse. Visible cysts and carcinomas were
counted and plotted  SD.
C. Tumours exceeding 0.5cm in diameter in 12–14 mice/genotype/time range analysed as in B  SD.
D. Left: representative MRI images of two 14-month-old mice of the indicated genotypes. Tumours are marked with dotted lines. A tumour exceeding 0.5cm in
diameter is indicated by a red arrow. Right: photograph of kidneys from mice of the indicated genotype sacrificed at 19 months of age.
E. H&E of a kidney carcinoma from a Tsc2
þ/  mouse. Dotted lines indicate tumour margins. Single arrow indicates the predominant papillary architecture, while
double arrows indicate an area of clear-cell phenotype. Scale bar: 100mM.
F. On the left, H&E of a sarcomatoid area in a kidney carcinoma from a Pml
 / Tsc2
þ/  mouse (scale bar: 100mM). Graph on the right represents the number of
tumours (n¼6, 7 and 10, respectively), with areas of sarcomatoid change from mice with the indicated genotype (SD¼0.458). p-values, calculated by
Student’s t-test, compare categories marked with asterisks and are indicated only when significant.
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conﬁrming that increased mTORC1 activity observed in pre-
cystic kidney and in cysts does not affect tumour initiation.
Finally, we askedif loss ofPml would surrogate for Tsc2 LOH,
which invariably occurs in human TSC tumours and kidney
tumours from Tsc2
þ/  mice (Green et al, 1994; Henske et al,
1996; Onda et al, 1999). Polymerase chain reaction (PCR)
analysis of large tumours of similar sizes showed that loss of
Pml signiﬁcantly diminished the rate of Tsc2 LOH (p¼0.006;
Fig 4E). Thus, the selective pressure to completely eliminate
Tsc2 in order to fully activate mTORC1 is alleviated in the
absence of Pml.Moreover, we found that mTORC1 activation is
slightly higher, although not signiﬁcantly, in Pml
 / Tsc2
þ/ 
tumours that have undergone Tsc2 LOH as compared to
those that have not (Supporting Information Fig 4), further
conﬁrming that loss of Pml and Tsc2 independently lead to
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Figure 3. Inactivation of Pml in Tsc2
þ/  tumours increases aggressiveness.
A. Microvessel density in kidney carcinomas measured by CD34 immunohistochemistry. Total number of vessels/20  field was counted in five fields/tumour in
three tumours/genotype  SD. On the left, representative images of CD34 staining in kidney carcinomas of the indicated genotype (scale bar: 100mM).
B. Total amount ofKi-67 positivecellsin 20 fieldswere counted in five fields/tumourin four tumours/genotype  SD.Ontheleft, representative images ofKI-67
staining in kidney carcinomas of the indicated genotype (scale bar: 50mM).
C. Percentage of gelsolin-positive and gelsolin-negative kidney cysts from age-matched mice of the indicated genotypes (n¼4 mice/genotype; 15 and 14 total
cysts, respectively).
D. Representative images of gelsolin immunohistochemistry in kidney carcinomas (scale bar: 100mM). Arrows indicate areas of intense gelsolin positivity.
p-values are calculated by Student’s t-test. All mice in Fig 3 were 14–19-month-old.
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Figure 4. Kidney tumours from Pml
 /  Tsc2
þ/  mice have increased mTORC1 activity and decreased Tsc2 LOH.
A. Immunohistochemical analysis of phospho-S6 and phospho-4EBP1 on kidney tumours of thesame size from age-matchedmice. 20 magnification (scale bar:
50mM). Higher magnification images of tumour areas are shown in indents.
B. Western blot analysis of phospho and total 4EBP1 and S6 performed on lysates form kidney tumours derived from age-matched mice of the indicated
genotype. Graphs at the bottom show mean relative ratios of phospho/total proteins from various western blots  SD.
C. Western blot analysis of phospho and total Akt, phospho-S6 and phospho-4EBP1 performed on lysates form normal kidneys or kidney tumours derived from
age-matched mice of the indicated genotype.
D. Percentage of phospho-S6-positive and -negative kidney cysts from age-matched mice (n¼4 mice/genotype; 8 cysts). p-value obtained comparing mice wt or
null for Pml¼0.07.
E. Upper panel: representative image of PCR-amplified wt and null Tsc2 alleles from tails and kidney tumours (tu.) of indicated genotypes. Bottom table: number
of tumours with loss of the wt Tsc2 allele. p-values, calculated by Student’s t-test, compare categories indicated with asterisks. All mice in Fig 4 were 14–19-
month-old.
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Tsc2 loss.
DISCUSSION
Our data indicate that PML is a physiological negative regulator
ofmTORC1activity,andthatthroughthisregulation,itrestrains
tumour progression in a mouse model of kidney tumourigenesis
initiated by Tsc2 inactivation. Surprisingly, Pml status does not
seem to affect Akt activation in this context. This could be
explained by a potent negative feedback loop triggered by
combined Pml and Tsc2 inactivation that impedes further
activation ofnuclearAktbylossofPml.Alternatively,theroleof
PML on Akt activation in the nucleus may be tissue speciﬁc and
less relevant in the kidney than in other organs, such as the
prostate (Trotman et al, 2006).
Importantly, we show that PML regulates kidney tumour
progression, but not cystogenesis and tumour onset. The other
relevant conclusion of our study is that high mTORC1 activity is
not sufﬁcient to initiate tumourigenesis in the kidney and may
not be the cause of hamartomatous and neoplastic growths in
tuberous sclerosis complex (TSC) patients, although it may
affect other functions that we have not analysed such as kidney
metabolism.
In agreement with our ﬁndings, a percentage of cysts from
Tsc1
þ/  and Tsc2
þ/  mice does not display mTORC1 activation
(Bonnet et al, 2009; Wilson et al, 2006). In addition in the Eker rat
model, a mutant Tsc2gene that fails to inhibit mTOR is still able to
suppress tumourigenesis (Shiono et al, 2008), and administration
of rapamycin reduces the development of macroscopic tumours
while having no effect on the number of microscopic precursor
lesions(Kenersonetal,2005).Indeed,theTsc1/Tsc2complexhas
been shown to possess other activities beside inhibiting mTORC1
(Bonnet et al, 2009; Lacher et al, in press), and it has been
suggested that renal cystogenesis in TSC and polycystic kidney
disease mouse models may be caused by defects in primary cilia
andcellpolarityviaanmTOR-independentpathway(Bonnetetal,
2009). Together with these studies, our work emphasizes that
mTOR activation may not be causative of the initial development
of the pathological growths that affect TSC patients.
BecausemanycurrentnewregimentsforthetreatmentofTSC
patients rely on the use of mTORC1 inhibitors (Sampson, 2009),
it is extremely important to determine the role of mTOR in the
pathogenesis of TSC. Our study suggests that for at least some
aspects of TSC pathology as well as kidney tumourigenesis,
mTORC1inhibitorsmayantagonizesomefeaturesofthedisease
but not others. Further work is thus required to identify
additional molecular targets whose modulation may potentiate
the efﬁcacy of current treatment modalities.
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The paper explained
PROBLEM:
Aberrant activation of mTORC1 has been reported in a large
number of human tumors. In renal carcinoma in particular, this
observation has led to the development of novel therapeutic
modalities, as mTOR inhibitors have been approved for the
treatment of this tumor type. Nevertheless, compelling genetic
evidence that the activation of this pathway may contribute to
initiation or progression of kidney tumorigenesis is still lacking.
Furthermore, genetic mutations in genes regulating the mTORC1
pathwayare rarelyfound insporadictumors,and when inherited
in the germ line, only lead to hamartomatous syndromes such as
Tuberous Sclerosis Complex. Thus, a firm genetic understanding
of the role of mTORC1 signaling in kidney tumorigenesis is
needed to more accurately guide the clinical use of the ever-
growing family of mTOR inhibitors.
RESULTS:
We generated a compound knockout mouse model lacking two
tumor suppressors that are known to negatively regulate mTOR.
Tsc2 heterozygosity leads to high mTORC1 activity and the
development of kidney cysts and, after a longer latency, to
carcinomas.AlthoughmTORC1activitywasfurtherelevatedinpre-
tumoralkidneysofcompoundPml-Tsc2mutantmice,kidneytumor
initiation was not affected. A further increase in mTORC1 activity,
however, affected tumor progression. Tumors from compound
mutant mice were more vascularized, displayed a higher
proliferation rate and a more aggressive histological profile.
Furthermore, loss of Pml in kidney tumors significantly reduced the
rate of loss of heterozygosity (LOH) of the wild-type Tsc2 allele
observed in advanced tumoral lesions. These findings provide
genetic evidence that Pml and Tsc2 negatively regulate mTORC1
activity,cooperativelysuppressingtumorprogressioninthekidney.
IMPACT:
Our study suggests that hyperactivation of mTORC1 does not
self-sufficiently trigger kidney cystogenesis and tumor initiation.
Novel approaches for the treatment of kidney cancer and
Tuberous Sclerosis Complex-related neoplasias are focused on
the use of mTOR inhibitors that mainly restrain mTORC1 activity.
However, most kidney tumors do not regress upon use of mTOR
inhibitors,andtumorsinpatientswithTuberousSclerosisregress
on therapy but tend to regrow after treatment is discontinued.
Further work is therefore required to identify the additional
pathways that are critically involved in initiation of kidney
tumors and Tuberous Sclerosis-associated lesions. Combining
mTORinhibitorswithtargetedtherapiesthattargetthesecritical
additional pathways may reveal in the future a more effective
strategy for treating cancer of the kidney and Tuberous Sclerosis
lesions.
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Mice
Pml
þ/  mice were crossed with Tsc2
þ/  mutant mice to generate all
combinations of compound mutant mice. All mice were of mixed 129/
Sv and C57BL/6 strains. For tumour onset analysis, five mice per
genotype were sacrificed at 6 and 8 months of age for microscopic
analysis of the kidneys. Prostate, spleen, liver and lung were also
analysed. For assessment of tumour progression, mice were subjected
to monthly magnetic resonance imaging (MRI) screening. Imaging
analysis and acquisition was performed as previously described
(Trotman et al, 2006). Animals were sacrificed when moribund. All
mice were cared for according to NIH-approved institutional animal
care guidelines and upon approval by the Institutional Animal Care
and Use Committee Beth Israel Deaconess Medical Center (IACUC
animal protocol 071-2008).
Histopathology and immunohistochemistry
Normal and tumour tissue samples were fixed in 4% paraformalde-
hyde for 48h, washed twice with PBS 1X and transferred to 70%
ethanol. Samples of kidneys, spleen, liver, lung, lymphonodes and
prostate were embedded in paraffin and sections 4–5mm of thickness
were stained with haematoxylin and eosin (H&E) according to
standard protocols.
For measuring the number of lesions per kidney, whole kidneys was
sectioned and H&E staining was performed on 1 every 15 sections.
Twelve H&E sections/mouse were analysed by certified pathologists.
Immunohistochemical analysis on kidney samples was performed
using the following antibodies: anti-PML (Chemicon), anti-Phospho S6
(S235/236) and anti-phospho-4EBP1 (Cell Signaling Technology),
anti-mTOR (Cell Signaling Technology), Thiazide-Sensitive NaCl
Cotrasporter (NCC) (Chemicon), anti-gelsolin antibody was kindly
provided by Dr. J. Kwiatkowsi, anti-Ki-67 (Novocastra), CD34 (Dako).
Loss of heterozygosity (LOH) analysis
LOH of Tsc2 allele was performed by PCR as previously described (Ma
et al, 2005). Tissues for LOH analysis were obtained from kidney
tumours of  0.5cm in diameter. Similar tumour areas (devoid of
haemorrhagic or necrotic lesions) were used for this analysis.
Preparation of tissue extracts and immunoblotting
Tissues were dissected and homogenized immediately on ice in RIPA
buffer [Trsi–HCl, pH 7.8 50mM, NaCl 150mM, NP40 1%, sodium
deoxycholate 0.5%, SDS 0.1%, protease inhibitor cocktail (Roche),
sodium orthovanadate 1mM, sodium fluoride 1mM, PMSF 1mM].
Insoluble material was removed by centrifugation for 20min at
13,000rpm at 48C. Protein samples were resolved by SDS–PAGE 10%
and transferred to a nitrocellulose membrane blocked in 5% nonfat
milk and blotted with the following antibodies: mouse anti-a-tubulin
(Sigma), anti-phospho-S6 (S235/236), anti-S6, anti-phospho 4E-BP1
(Ser65) and anti-4EBP1 (Cell Signaling Technology).
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